The FDA's decision directly impacts Dynavax's ability to bring the four-dose HEPLISAV-B regimen to market. Without sufficient data to prove effectiveness or safety, the approval process could be significantly delayed or even halted, affecting the company's potential revenue and growth in the short term. This news is likely to be viewed negatively by investors, potentially leading to a decrease in stock price.